Kymriah® (tisagenlecleucel) – New indication
May 28, 2022 - Novartis announced the FDA approval of Kymriah (tisagenlecleucel), for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
Download PDF
